RFX5
A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS; MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined. [provided by RefSeq]
Full Name
regulatory factor X, 5 (influences HLA class II expression)
Function
Activates transcription from class II MHC promoters. Recognizes X-boxes. Mediates cooperative binding between RFX and NF-Y. RFX binds the X1 box of MHC-II promoters.
Biological Process
Biological Process negative regulation of transcription by RNA polymerase IIIEA:Ensembl
Biological Process positive regulation of MHC class II biosynthetic process1 PublicationIC:ComplexPortal
Biological Process positive regulation of transcription by RNA polymerase IIManual Assertion Based On ExperimentIDA:NTNU_SB
Biological Process regulation of transcription by RNA polymerase IIManual Assertion Based On ExperimentIBA:GO_Central
Biological Process positive regulation of MHC class II biosynthetic process1 PublicationIC:ComplexPortal
Biological Process positive regulation of transcription by RNA polymerase IIManual Assertion Based On ExperimentIDA:NTNU_SB
Biological Process regulation of transcription by RNA polymerase IIManual Assertion Based On ExperimentIBA:GO_Central
Cellular Location
Nucleus
Involvement in disease
Bare lymphocyte syndrome 2 (BLS2):
A severe combined immunodeficiency disease with early onset. It is characterized by a profound defect in constitutive and interferon-gamma induced MHC II expression, absence of cellular and humoral T-cell response to antigen challenge, hypogammaglobulinemia and impaired antibody production. The consequence include extreme susceptibility to viral, bacterial and fungal infections.
A severe combined immunodeficiency disease with early onset. It is characterized by a profound defect in constitutive and interferon-gamma induced MHC II expression, absence of cellular and humoral T-cell response to antigen challenge, hypogammaglobulinemia and impaired antibody production. The consequence include extreme susceptibility to viral, bacterial and fungal infections.
View more
Anti-RFX5 antibodies
+ Filters
Loading...
Target: RFX5
Host: Mouse
Specificity: Human
Clone: C-3
Application*: WB, IP, IF, E
Target: RFX5
Host: Mouse
Antibody Isotype: IgG2a
Specificity: Human
Clone: CBCNR-443
Application*: WB
Target: RFX5
Host: Mouse
Antibody Isotype: IgG2a, κ
Specificity: Human
Clone: 3B8
Application*: E, WB
Target: RFX5
Host: Mouse
Antibody Isotype: IgG2a
Specificity: Human
Clone: 1E5
Application*: IP, M
Target: RFX5
Host: Mouse
Antibody Isotype: IgG1
Specificity: Human
Clone: 1D11
Application*: IP, M, WB
Target: RFX5
Host: Mouse
Antibody Isotype: IgG2a
Specificity: Human
Clone: 1C12
Application*: IP, M
More Infomation
Hot products 
-
Mouse Anti-ANXA7 Recombinant Antibody (A-1) (CBMAB-A2941-YC)
-
Mouse Anti-AZGP1 Recombinant Antibody (CBWJZ-007) (CBMAB-Z0012-WJ)
-
Rabbit Anti-ALK (Phosphorylated Y1278) Recombinant Antibody (D59G10) (PTM-CBMAB-0035YC)
-
Mouse Anti-ALPL Antibody (B4-78) (CBMAB-1009CQ)
-
Rat Anti-C5AR1 Recombinant Antibody (8D6) (CBMAB-C9139-LY)
-
Mouse Anti-ALX1 Recombinant Antibody (96k) (CBMAB-C0616-FY)
-
Mouse Anti-BCL6 Recombinant Antibody (CBYY-0435) (CBMAB-0437-YY)
-
Mouse Anti-dsDNA Recombinant Antibody (22) (CBMAB-AP1954LY)
-
Mouse Anti-CASQ1 Recombinant Antibody (CBFYC-0863) (CBMAB-C0918-FY)
-
Mouse Anti-ACO2 Recombinant Antibody (V2-179329) (CBMAB-A0627-YC)
-
Human Anti-SARS-CoV-2 S1 Monoclonal Antibody (CBFYR-0120) (CBMAB-R0120-FY)
-
Mouse Anti-FeLV g27 Recombinant Antibody (1) (CBMAB-V208-1714-FY)
-
Mouse Anti-AMOT Recombinant Antibody (CBYC-A564) (CBMAB-A2552-YC)
-
Rat Anti-AChR Recombinant Antibody (V2-12500) (CBMAB-0990-CN)
-
Mouse Anti-AFDN Recombinant Antibody (V2-58751) (CBMAB-L0408-YJ)
-
Mouse Anti-DLC1 Recombinant Antibody (D1009) (CBMAB-D1009-YC)
-
Mouse Anti-BPGM Recombinant Antibody (CBYY-1806) (CBMAB-2155-YY)
-
Mouse Anti-AP4E1 Recombinant Antibody (32) (CBMAB-A2996-YC)
-
Rabbit Anti-CCN1 Recombinant Antibody (CBWJC-3580) (CBMAB-C4816WJ)
-
Mouse Anti-CDKL5 Recombinant Antibody (CBFYC-1629) (CBMAB-C1689-FY)
For Research Use Only. Not For Clinical Use.
(P): Predicted
* Abbreviations
- AActivation
- AGAgonist
- APApoptosis
- BBlocking
- BABioassay
- BIBioimaging
- CImmunohistochemistry-Frozen Sections
- CIChromatin Immunoprecipitation
- CTCytotoxicity
- CSCostimulation
- DDepletion
- DBDot Blot
- EELISA
- ECELISA(Cap)
- EDELISA(Det)
- ESELISpot
- EMElectron Microscopy
- FFlow Cytometry
- FNFunction Assay
- GSGel Supershift
- IInhibition
- IAEnzyme Immunoassay
- ICImmunocytochemistry
- IDImmunodiffusion
- IEImmunoelectrophoresis
- IFImmunofluorescence
- IGImmunochromatography
- IHImmunohistochemistry
- IMImmunomicroscopy
- IOImmunoassay
- IPImmunoprecipitation
- ISIntracellular Staining for Flow Cytometry
- LALuminex Assay
- LFLateral Flow Immunoassay
- MMicroarray
- MCMass Cytometry/CyTOF
- MDMeDIP
- MSElectrophoretic Mobility Shift Assay
- NNeutralization
- PImmunohistologyp-Paraffin Sections
- PAPeptide Array
- PEPeptide ELISA
- PLProximity Ligation Assay
- RRadioimmunoassay
- SStimulation
- SESandwich ELISA
- SHIn situ hybridization
- TCTissue Culture
- WBWestern Blot
Online Inquiry



